Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level Bio ABFRA:4MB -6.25%23 EV-to-EBIT is -6.38 as of Jul. 27, 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 961537.5% on this metric.
The historical rank and industry rank for Level Bio AB's EV-to-EBIT or its related term are showing as below:
FRA:4MB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.09 Med: -4.62 Max: -1.22
Current: -6.48
During the past 13 years, the highest EV-to-EBIT of Level Bio AB was -1.22. The lowest was -8.09. And the median was -4.62.
FRA:4MB's EV-to-EBIT is ranked worse than 100% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.47
vs FRA:4MB: -6.48
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Level Bio AB's Enterprise Value for the quarter that ended in Mar. 2026 was €1.10 Mil.
Level Bio AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Bio AB EV-to-EBIT Related Terms
Level Bio AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Level Bio AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Level Bio AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Level Bio AB's EV-to-EBIT falls into.
Level Bio AB's current Enterprise Value is €1.58 Mil.
Level Bio AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Bio AB (FRA:4MB) has a EV-to-EBIT of -6.38 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Level Bio AB and its competitors. According to the industry distribution chart, Level Bio AB ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry.
Is Level Bio AB's EV-to-EBIT too high?
Level Bio AB's current EV-to-EBIT is -6.38. Based on the distribution chart, Level Bio AB ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #999999 out of 104 companies for EV-to-EBIT. This places Level Bio AB in the lower half of its industry. The industry median EV-to-EBIT is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.47, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current EV-to-EBIT is -6.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current EV-to-EBIT of -6.38. The current EV-to-EBIT is -6.38. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current EV-to-EBIT is -6.38 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
